Li Tianen, Su Wei, Wang Zhiqiang, Wang Xiao, Ma Xiaoguang, Zhao Rui
Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, No.107 Wenxi Road, Jinan, 250012, Shandong, People's Republic of China.
Department of Hepatobiliary Surgery, Qinghai Red Cross Hospital, Xining, 810000, Qinghai, People's Republic of China.
Eur J Med Res. 2025 Jul 14;30(1):620. doi: 10.1186/s40001-025-02888-7.
Gastric cancer (GC) is a highly heterogeneous and complex disease. Recently, integrin β (ITGB) superfamily members have been shown to play crucial roles in the initiation and progression of various human cancers. However, the precise role and molecular mechanisms of ITGB1 in GC are yet to be fully elucidated.
This bioinformatics and clinical study systematically analyzed the pan-cancer expression patterns and prognostic significance of ITGBs using data from The Cancer Genome Atlas and Genotype-Tissue Expression portals. Multivariate regression analysis was performed to identify key factors influencing GC prognosis. Candidate noncoding RNAs (ncRNAs) potentially regulating ITGB1 expression were identified via expression profiling, coexpression assessment, and survival correlation studies. Furthermore, the associations of ITGB1 and its related long ncRNA MIR99AHG with tumor-infiltrating immune cells, immune cell markers, and immune checkpoint molecules in GC were explored.
Compared with adjacent normal tissues, the ITGB1, ITGB2, ITGB4, ITGB5, and ITGB8 mRNA levels were significantly upregulated in GC tissues (p < 0.05). Cox regression and Kaplan-Meier survival analyses indicated that ITGB1 upregulation was associated with poor prognosis (univariable hazards ratio = 1.40, 95% confidence interval 1.008-1.956, p = 0.045) and served as an independent prognostic factor (multivariate hazards ratio = 1.46, 95% confidence interval 1.004-2.140, p = 0.048) in patients with GC. The MIR99AHG/hsa-mir-17-5p axis (r = - 0.56, p < 0.001) was identified as the most promising upstream ncRNA-related pathway regulating ITGB1 expression in GC. In addition, ITGB1 expression in GC and adjacent nontumorous tissues was validated using immunohistochemistry (H-score: 35.4 ± 19.2 vs. 28.4 ± 16.2, respectively; p = 0.035). MIR99AHG expression was similarly assessed through in situ hybridization (H-score: 32.4 ± 15.6 vs. 20.5 ± 11.0, respectively; p < 0.001). There was a positive correlation between ITGB1 expression and infiltrating CD4 + T cells (r = 0.17, p < 0.001), M2 macrophages (r = 0.37, p < 0.001), dendritic cells (r = 0.19, p < 0.001), and immune checkpoints (PD-L1, CTLA-4, and CD28). Particularly, high macrophage infiltration was associated with favorable prognosis in GC (p = 0.004).
Our findings suggest that ncRNA-mediated ITGB1 expression is associated with poor prognosis and tumor-immune infiltration in GC. However, further validation through extensive mechanistic studies and large-scale clinical trials is warranted.
胃癌(GC)是一种高度异质性和复杂性的疾病。最近,整合素β(ITGB)超家族成员已被证明在各种人类癌症的发生和发展中起关键作用。然而,ITGB1在GC中的精确作用和分子机制尚未完全阐明。
本生物信息学和临床研究使用来自癌症基因组图谱和基因型-组织表达数据库的数据,系统分析了ITGBs的泛癌表达模式和预后意义。进行多变量回归分析以确定影响GC预后的关键因素。通过表达谱分析、共表达评估和生存相关性研究,鉴定了可能调节ITGB1表达的候选非编码RNA(ncRNA)。此外,还探讨了ITGB1及其相关长链ncRNA MIR99AHG与GC中肿瘤浸润免疫细胞、免疫细胞标志物和免疫检查点分子的关联。
与相邻正常组织相比,GC组织中ITGB1、ITGB2、ITGB4、ITGB5和ITGB8的mRNA水平显著上调(p < 0.05)。Cox回归和Kaplan-Meier生存分析表明,ITGB1上调与预后不良相关(单变量风险比 = 1.40,95%置信区间1.008 - 1.956,p = 0.045),并且是GC患者的独立预后因素(多变量风险比 = 1.46,95%置信区间1.004 - 2.140,p = 0.048)。MIR99AHG/hsa-mir-17-5p轴(r = -0.56,p < 0.001)被确定为GC中调节ITGB1表达最有前景的上游ncRNA相关途径。此外,使用免疫组织化学验证了GC和相邻非肿瘤组织中ITGB1的表达(H评分:分别为35.4±19.2和28.4±16.2;p = 0.035)。通过原位杂交类似地评估了MIR99AHG的表达(H评分:分别为32.4±15.6和20.5±11.0;p < 0.001)。ITGB1表达与浸润性CD4 + T细胞(r = 0.17,p < 0.001)、M2巨噬细胞(r = 0.37,p < 0.001)、树突状细胞(r = 0.19,p < 0.001)和免疫检查点(PD-L1、CTLA-4和CD28)之间存在正相关。特别是,高巨噬细胞浸润与GC的良好预后相关(p = 0.004)。
我们的研究结果表明,ncRNA介导的ITGB1表达与GC的不良预后和肿瘤免疫浸润相关。然而,需要通过广泛的机制研究和大规模临床试验进行进一步验证。